Kodiak Sciences Inc. (KOD)

USD 8.75

(-1.35%)

Market Cap (In USD)

460.45 Million

Revenue (In USD)

-

Net Income (In USD)

-260.49 Million

Avg. Volume

237.38 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.19-11.6
PE
-
EPS
-
Beta Value
2.251
ISIN
US50015M1099
CUSIP
50015M109
CIK
1468748
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Victor Perlroth M.D.
Employee Count
-
Website
https://kodiak.com
Ipo Date
2018-10-04
Details
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.